PDC*line Pharma completes enrolment of four cohorts of patients     
in PDC-LUNG-101 phase I/II clinical trial.

Total of 67 patients dosed in four cohorts in PDC-LUNG-101 trial with PDC*lung01...

We are very pleased to announce the publication of a new article with an interview of our CEO Eric Halioua published this week in the magazine PharmaBoardroom, the global platform for healthcare &...

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial

We are very pleased to announce that a new article, following an interview of...

PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The...

We are delighted to announce that our CEO will be presenting at the 6th Europe Neoantigen Summit 2023 hosted by Hanson Wade in Amsterdam (Netherlands) from April 24-26th! He will be presenting PDC...

We are very pleased to inform you about the publication of a new scientific paper in the peer-reviewed journal "Genes and Cancer" as a "Research Perspective". Article is entitled: Leveraging a...

We are very pleased to inform you about the publication of a new scientific article in the "International Journal of Molecular Sciences" in a special issue entitled "Dendritic Cell and Cancer Therapy...

Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab

Liège, Belgium, and Grenoble, France...

PDC*line Pharma will be presenting a poster at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress taking place from 7 to 9 December 2022, in Geneva, Switzerland...

We are delighted to announce that our CEO Eric Halioua will make a company presentation and will be panelist at the Finance and Investment track organized by Festival of Biologics in Basel on November...